Ritu has worked in the field of drug development for more than 20 years, building and leading teams and translating complex processes into clear, actionable steps.

Prior to Disarm, Ritu was Vice President, Project Management and Clinical Operations, at Summit Therapeutics. In this role, she led a cross-functional team to deliver near and long-term strategies for the Duchenne muscular dystrophy (DMD) and Clostridium difficile (C. diff) programs. Before Summit, she held roles of increasing responsibility at Sanofi-Aventis, Quintiles, Genentech and Hoffmann La-Roche in program management, preclinical development, clinical operations and manufacturing.

Ritu has a BS and a Master of Science degree from the University of Bombay, as well as an MBA from Duke’s Fuqua School of Business’s Global Executive Program.

Jason is a founder and the executive chairman and acting CEO of Disarm Therapeutics. He is a partner at Atlas Venture where he focuses on the creation, development, and business strategy of novel therapeutics companies. He is a founder and the chairman, and was previously the founding CEO, of Generation Bio, and currently serves on the boards of Replimune, Gemini Therapeutics, Accent Therapeutics, and Bicycle Therapeutics.

Prior to joining Atlas, Jason was president of Epizyme (NASDAQ: EPZM), where he charted the company’s strategic course from a private, research-stage business into the clinic and through partnerships with Celgene, GSK and others and a successful IPO in 2013. Prior to Epizyme, Jason led business development at Alnylam (NASDAQ: ALNY), where he was a member of the leadership team and responsible for partnerships with Roche, Takeda, GSK, Ionis, and others. Before Alnylam, Jason was a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Mersana Therapeutics (NASDAQ: MRSN).

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the BIDMC Board of Overseers, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council.

Raul is VP, Head of Biology and co-founder of Disarm Therapeutics. He was previously Co-Head, North America, of the Neurology Disease Area Team (NeuroDAT) at Vertex Pharmaceuticals, where he led a strategic and scientific committee responsible for all early stage Neurology Programs. While at Vertex, he also served as the Multiple Sclerosis Disease Area Expert, and as the research representative on the late development team that prepared the IND submission for VX-210, an experimental drug for spinal cord injury. Experienced in forming and leading teams in drug discovery and target prosecution, he was a major initiator or contributor to discovery projects in disorders of the central nervous system involving axo-glial communication, myelination, glial cell biology, and axonal degeneration and protection.

Raul previously held roles as Director of Neurosciences at AlphaGene, and in neuroscience discovery research at Biogen-Idec and Genetics Institute/Wyeth. Raul earned his PhD in Neurobiology from Harvard University, under the supervision of Gerald Fischbach, followed by a postdoctoral fellowship in the Department of Neurobiology at Harvard Medical School. He has served on ad-hoc NIH review panels for spinal cord trauma and brain cancer research, has several publications and patent applications, and authored a chapter in “Culturing Nerve Cells” (Banker and Goslin, Eds, MIT Press), a standard textbook in the field.

Peter joins Disarm Therapeutics from Selecta Biosciences, where he held the position of Chief Business Officer and led the company’s gene therapy programs from 2011 to 2017. During his tenure at Selecta, he directed the product and business strategy leading to a $70 million IPO and multi-billion dollar deals with Sanofi and Spark Therapeutics.

Prior to Selecta, Peter was Vice President, Head of Mergers & Acquisitions and Alliance Management at Solvay Pharmaceuticals, where he negotiated license and acquisition agreements in various therapeutic areas such as vaccines, neurology and cardiology. He was the lead negotiator for the $1.5 billion fenofibrate alliance between Solvay Pharmaceuticals and Abbott Laboratories and was instrumental in the $6.2 billion acquisition of Solvay Pharmaceuticals by Abbott Laboratories. Peter was then appointed by Abbott to lead the post-merger integration resulting in the spin-out of what became AbbVie.

Earlier in his career, he spent nearly a decade as a management consultant at McKinsey & Company and Simon Kucher & Partners. Peter received his MSc. in Industrial Engineering and Management from the Karlsruhe Institute of Technology in Germany.